Ulcerative Colitis Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates

DelveInsight's "Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Ulcerative Colitis, historical and forecasted epidemiology as well as the Ulcerative Colitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Ulcerative Colitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Ulcerative Colitis Market Forecast https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Ulcerative Colitis Market Report:
• The Ulcerative Colitis market size was valued approximately USD 8,400 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In October 2025, The U.S. FDA approved mirikizumab-mrkz (Omvoh) as a once-monthly, single-injection maintenance treatment for adults with ulcerative colitis. Developed by Eli Lilly, the approval is based on a Phase 1 study comparing a 1,200 mg/2 mL subcutaneous injection with the previously approved two 100 mg/1 mL injections, demonstrating bioequivalence between the new single-dose and the original two-dose regimen.
• In May 2025, ALPCO announced the European launch of its Calprotectin Immunoturbidimetric Assay to aid in diagnosing inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. Already FDA-cleared and IVDD-certified, the assay assists in differentiating IBD from irritable bowel syndrome (IBS) when combined with other clinical information.
• In May 2025, Teva Pharmaceuticals and Alvotech announced that the FDA has approved SELARSDITM (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab). Beginning April 30, 2025, SELARSDI will be available in all formulations equivalent to the reference product, for treating adults and pediatric patients with psoriatic arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis.
• In March 2025, Celltrion announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), after receiving FDA approval in December 2024. STEQEYMA is approved for the same indications as STELARA, providing consistent treatment options for patients and healthcare providers.
• In January 2025, Rise Therapeutics announced that the FDA has accepted its IND application to initiate a Phase 1 cancer trial for R-5780, representing the company's fourth clinical program. Its other ongoing studies target ulcerative colitis, rheumatoid arthritis, and type 1 diabetes.
• In 2023, the United States held the largest ulcerative colitis market among the 7 major markets (7MM), with a value of around USD 5,900 million, and this is projected to grow further by 2034.
• In 2023, the total diagnosed prevalence of ulcerative colitis across the 7 major markets (7MM) was around 3,114,000 cases, with numbers expected to rise over the forecast period.
• In 2023, the United States accounted for the largest share of diagnosed ulcerative colitis cases in the 7MM, representing approximately 47%, while Germany and Japan each contributed about 10% of the total population.
• DelveInsight estimates that in 2023, the EU4 and the UK had around 521,000 diagnosed mild cases and 860,000 diagnosed moderate-to-severe cases of ulcerative colitis. These numbers are expected to rise over the forecast period.
• In the United States, treatments approved for moderate to severe ulcerative colitis include anti-TNFα agents (adalimumab, infliximab, golimumab), interleukin inhibitors (ustekinumab, mirikizumab), anti-integrin therapy (vedolizumab), the S1P receptor modulator ozanimod, and JAK inhibitors (tofacitinib, upadacitinib).
• Emerging therapies such as obefazimod (Abivax), risankizumab (AbbVie/Boehringer Ingelheim), guselkumab (Janssen), and others are expected to broaden the treatment options for ulcerative colitis.
• Key Ulcerative Colitis Companies: Janssen Pharmaceuticals, Takeda Pharmaceuticals, Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, Vedanta Biosciences, Inc., Palatin Technologies, Inc, Eli Lilly and Company, Genentech, Inc., Pfizer, Amgen, AbbVie, Landos Biopharma Inc., Ferring Pharmaceuticals, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma Ltd, EA Pharma Co., Ltd., and others
• Key Ulcerative Colitis Therapies: SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), VE202, PL8177 Placebo, Mirikizumab, Vixarelimab, Etrasimod, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, and others
• The Ulcerative Colitis epidemiology based on severity-based cases analyzed that moderate-to-severe UC cases accounts for ~55% of the total cases and the rest of the cases falls under mild category.
• The Ulcerative Colitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Ulcerative Colitis pipeline products will significantly revolutionize the Ulcerative Colitis market dynamics.

Ulcerative Colitis Overview
Ulcerative Colitis is a chronic inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers in the lining of the colon and rectm. It leads to symptoms such as abdominal pain, diarrhea (often with blood), urgency to defecate, and fatigue. The exact cause is unknown, but it involves an abnormal immune response, genetic factors, and environmental triggers. UC is a lifelong condition requiring medical management to control inflammation and prevent complications.

Get a Free sample for the Ulcerative Colitis Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ulcerative Colitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Ulcerative Colitis Epidemiology Segmentation:
The Ulcerative Colitis market report proffers epidemiological analysis for the study period 2030-2034 in the 7MM segmented into:
• Total Prevalence of Ulcerative Colitis
• Prevalent Cases of Ulcerative Colitis by severity
• Gender-specific Prevalence of Ulcerative Colitis
• Diagnosed Cases of Episodic and Chronic Ulcerative Colitis

Download the report to understand which factors are driving Ulcerative Colitis epidemiology trends @ Ulcerative Colitis Epidemiology Forecast
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ulcerative Colitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Ulcerative Colitis market or expected to get launched during the study period. The analysis covers Ulcerative Colitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Ulcerative Colitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Ulcerative Colitis Therapies and Key Companies
• SIMPONI (golimumab): Janssen Pharmaceuticals
• ENTYVIO (vedolizumab): Takeda Pharmaceuticals
• Etrasimod (APD334): Arena Pharmaceuticals/Pfizer
• ABX464 (obefazimod): Abivax
• SHR0302 (Ivarmacitinib): Reistone Biopharma
• VE202: Vedanta Biosciences, Inc.
• PL8177 Placebo: Palatin Technologies, Inc
• Mirikizumab: Eli Lilly and Company
• Vixarelimab: Genentech, Inc.
• Etrasimod: Pfizer
• Efavaleukin alfa: Amgen
• ABBV-668: AbbVie
• NX-13: Landos Biopharma Inc.
• 5-ASA: Ferring Pharmaceuticals
• Remestemcel-L: Mesoblast, Inc.
• Ozanimod: Bristol-Myers Squibb
• VTX002: Oppilan Pharma Ltd
• AJM300: EA Pharma Co., Ltd.

Discover more about therapies set to grab major Ulcerative Colitis market share @ Ulcerative Colitis Treatment Landscape
https://www.delveinsight.com/sample-request/ulcerative-colitis-uc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Ulcerative Colitis Market Strengths
• With the market dynamics shifting towards medications with oral ROA, emergence of therapies like, BT-11, AJM300, Etrasimod, and SHR0302 will further drive the UC therapeutic market.
• Robust emerging pipeline with novel MOAs with less immunogenicity such as cobitolimod, BBT-401, Omilancor, and others are likely to strengthen the market.

Ulcerative Colitis Market Opportunities
• There lies tremendous potential in the UC landscape for drugs with better clinical profile especially in terms of safety. Safety concerns associated with JAK inhibitors poses a great opportunity for pharmaceutical companies to work on this front and improve the safety profile ofupcoming drugs.
• Limited treatment options available in case of relapsed or refractory pool, provides lucrative opportunities in the UC therapeutic space.

Scope of the Ulcerative Colitis Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Ulcerative Colitis Companies: Janssen Pharmaceuticals, Takeda Pharmaceuticals, Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, Vedanta Biosciences, Inc., Palatin Technologies, Inc, Eli Lilly and Company, Genentech, Inc., Pfizer, Amgen, AbbVie, Landos Biopharma Inc., Ferring Pharmaceuticals, Mesoblast, Inc., Bristol-Myers Squibb, Oppilan Pharma Ltd, EA Pharma Co., Ltd., and others
• Key Ulcerative Colitis Therapies: SIMPONI (golimumab), ENTYVIO (vedolizumab), Etrasimod (APD334), ABX464 (obefazimod), SHR0302 (Ivarmacitinib), VE202, PL8177 Placebo, Mirikizumab, Vixarelimab, Etrasimod, Efavaleukin alfa, ABBV-668, NX-13, 5-ASA, Remestemcel-L, Ozanimod, VTX002, AJM300, and others
• Ulcerative Colitis Therapeutic Assessment: Ulcerative Colitis current marketed and Ulcerative Colitis emerging therapies
• Ulcerative Colitis Market Dynamics: Ulcerative Colitis market drivers and Ulcerative Colitis market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Ulcerative Colitis Unmet Needs, KOL's views, Analyst's views, Ulcerative Colitis Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.